Last reviewed · How we verify
Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
The purpose of this study is to see whether serious graft versus host disease which is not well controlled with steroid treatment can be controlled with therapy with both daclizumab and infliximab. We hypothesize that a combination of daclizumab and infliximab will more effectively treat graft versus host disease than therapy with a single drug. The study also looks at whether chronic graft versus host disease develops, and survival at 6 and 9 months post-treatment.
Details
| Lead sponsor | University of Iowa |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 3 |
| Start date | 2006-01 |
| Completion | 2008-08 |
Conditions
- Graft vs Host Disease
Interventions
- daclizumab, infliximab
Primary outcomes
- Complete or partial response of GVHD to treatment according to standard staging/grading scale — 28 days
Countries
United States